Drug intelligence / Profile preview

GQ1007

Development stage: Unknown
Lead developer: GeneQuantum Biosciences
Administration: Intravenous

Overview

**GQ1007** is a first-in-class **antibody immune agonist conjugate (AIAC)** developed by GeneQuantum Healthcare using their proprietary intelligent ligase-dependent conjugation (iLDC) platform with a stable linker technology. It consists of a HER2-targeting antibody conjugated to a potent **TLR7/8 agonist** payload, enabling precise tumor-targeted delivery to enhance innate and adaptive immune responses by activating dendritic cells and macrophages, increasing T-cell infiltration, and converting "cold" tumors to "hot" tumors for improved immunotherapy efficacy, particularly in HER2-expressing solid tumors.[1][3][5][6]

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on GQ1007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ1007.

Explore the full profile